首页> 外文OA文献 >Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

【2h】

Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

机译：VISMODEGIB，刺猬抑制剂，与吉西他滨和NAB-PACLITAXEL联合未处理转移性胰腺腺癌患者的第2阶段研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Ana De Jesus-Acosta; Elizabeth A. Sugar; Peter J. O’Dwyer; Ramesh K. Ramanathan; Daniel D. Von Hoff; Zeshaan Rasheed; Lei Zheng; Asma Begum; Robert Anders; Anirban Maitra; Florencia McAllister; N. V. Rajeshkumar; Shinichi Yabuuchi; Roeland F. de Wilde; Bhavina Batukbhai; Ismet Sahin; Daniel A. Laheru;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma [J] . Kimmie Ng, Andrew Hendifar, Alexer Starodub, Investigational new drugs. . 2019,第1期

机译：Memelotinib的第1期剂量升级研究，Janus激酶1/2抑制剂，与吉西他滨和Nab-Parlitaxel联合在先前未处理的转移性胰腺导管腺癌患者中
2. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer [J] . Journal of Clinical Oncology . 2015,第36期

机译：吉西他滨加安慰剂或Vismodegib（一种刺猬通路抑制剂）在转移性胰腺癌患者中的随机Ib / II期研究
3. Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma [J] . Kim Edward J., Sahai Vaibhav, Abel Ethan V., Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第23期

机译：转移性胰腺癌患者中刺猬通路抑制剂GDC-0449（Vismodegib）与吉西他滨联用的临床试验研究
4. 3D ultrasonic molecular imaging to assess the efficacy of an aurora kinase inhibitor in pancreatic adenocarcinoma [C] . Streeter Jason E., Herrera Gabriela, Cao Joey, 2011 IEEE International Ultrasonics Symposium . 2011

机译：3D超声分子成像可评估极光激酶抑制剂在胰腺腺癌中的疗效
5. ZNF300 may influence the metastatic properties in pancreatic ductal adenocarcinoma. [D] . Fisher, Amanda. 2014

机译：ZNF300可能影响胰腺导管腺癌的转移特性。
6. Phase 2 study of vismodegib a hedgehog inhibitor combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma [O] . Ana De Jesus-Acosta, Elizabeth A. Sugar, Peter J. O’Dwyer, 2020

机译：VISMODEGIB刺猬抑制剂与吉西他滨和NAB-PACLITAXEL联合未处理转移性胰腺腺癌患者的第2阶段研究
7. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer [O] . S. Lindsey Davis, Dana B. Cardin, Safi Shahda, 2019

机译：WNT途径抑制剂Vantictimab与Nab-Paclitaxel和吉西他滨组合患者中的患者中的1B级剂量升级研究，以前未经处理的转移性胰腺癌

Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

著录项

引文网络

相似文献

相关主题

期刊订阅